Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning

NCT ID: NCT05471882

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

240000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2027-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite emerging efforts to decrease residual paralysis and postoperative complications with the use of quantitative neuromuscular monitoring and reversal agents their incidences remain high. In an optimal setting, neuromuscular blocking agents are dosed in a way that there is no residual block at the end of surgery. The effect of neuromuscular blocking agents, however, is highly variable and is not only influenced by their dose, but also by several patient-related factors such as muscle status, metabolic activity, and anesthesia management. Accordingly, the duration of action is difficult to predict.

The PINES project will use artificial intelligence methods to develop a model that can accurately predict the course of action of neuromuscular blocking agents. It will be used to predict time to complete neuromuscular recovery (train-of-four \[TOF\] ratio \>0.9) and may provide as a decision support in the individual management of timing and dosing of neuromuscular blocking drugs and their reversal agents.

In a secondary analysis, the association between the choice of neuromuscular blocking agent and postoperative pulmonary complications will be evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the PINES project is to identify a model that can accurately predict 1) time to complete neuromuscular recovery, 2) optimal timing and dose of neuromuscular blocking agents at each time point during surgery, and 3) TOF ratio at the estimated end of surgery to assess residual paralysis. Furthermore, a prospective clinical pilot study will be conducted to compare anesthesiologist-predicted neuromuscular recovery with that of the algorithm.

The project consists of two main objectives:

I. Big data analysis

* Establishing a data warehouse: Electronic registry data will be used.
* Generation of prediction models: Classification models will first be used to identify and weight the relevant parameters collected during premedication and intraoperatively. These will form the basis for the training cohort, which can then be used to carry out a simulated real-time analysis of the data. To compare the models, the loss functions mean squared error, mean absolute error and Huber Loss will be calculated.

II. Prospective comparison of the prediction: machine-learning model vs. anesthesiologist

Using the validated final prediction model with the best accuracy, we will perform a prospective clinical pilot study. The cohort will include prospectively enrolled adult surgical patients undergoing general anesthesia with a single dose of rocuronium for neuromuscular blockade. For each enrolled case, both the PINES algorithm and an experienced anesthesiologist will estimate the time to neuromuscular recovery, defined as a train-of-four (TOF) ratio \> 0.9.

At anesthesia induction, following administration of the neuromuscular blocking agent, participating specialist-level anesthesiologists will prospectively estimate the time in minutes until recovery of neuromuscular transmission. The PINES machine-learning model will generate its prediction. The actual recovery time will be determined from the continuously recorded intraoperative TOF measurements.

The agreement between the predicted and observed recovery times will be assessed by calculating the difference between predicted and actual values, as well as by determining inter-rater correlation coefficients comparing anesthesiologist predictions, algorithm predictions, and the measured recovery times.

In a secondary analysis, there will be evaluated whether the choice of neuromuscular blocking agent influences postoperative pulmonary complication risk in adult patients. Confounding will be addressed using statistical methods based on a causal inference framework.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Residual Paralysis, Post Anesthesia Postoperative Complications Neuromuscular Blockade Quantitative Neuromuscular Monitoring

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Neural Networks, Computer Monitoring, Intraoperative Artificial Intelligence Time Factors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single neuromuscular blocking agent dose

Patients receiving a single dose of neuromuscular blocking agent

No interventions assigned to this group

Incremental doses of neuromuscular blocking agents

Patients receiving repetitive doses of neuromuscular blocking agents

No interventions assigned to this group

Pharmacological reversal

Patients receiving pharmacological reversal of neuromuscular block

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (≥18 years) undergoing non-cardiac surgery receiving general anesthesia with intraoperative neuromuscular blocking agent administration and available TOF data.

Exclusion Criteria

* none
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Technical University of Munich

OTHER

Sponsor Role collaborator

University Hospital Ulm

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Flora Scheffenbichler

Clinician Scientist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manfred Blobner, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesiology and Intensive Care Medicine, University of Ulm,Ulm, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ulm

Ulm, Baden-Wurttemberg, Germany

Site Status

Technical University Munich

Munich, Bavaria, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TOF-R Prediction

Identifier Type: -

Identifier Source: org_study_id